DUNDEE, Scotland, July 6, 2012 /PRNewswire/ --
The medium term results of a 'First in Man' structured registry study are due to be published in the October issue of the Annals of Vascular Surgery. This significant paper describes a 40 patient, 10 centre study by leading vascular surgeons and doctors on patients with peripheral arterial disease needing an above-the-knee or below-the-knee bypass graft.
Peripheral arterial disease affects up to 20% of people over the age of 70. Patients are at high risk for cardiovascular events in the future, especially those needing bypass surgery. Improvements in bypass surgery techniques and devices are therefore very significant and a large number of people could benefit. This study demonstrates the validity of the concept of Spiral Laminar Flow(TM). It shows patient outcomes equivalent to, or exceeding, any known prosthetic grafts, including Heparin bonded grafts.
Vascular Flow Technologies is a medical device company operating within the peripheral vascular market. Its revolutionary and unique Spiral Laminar Flow(TM) technology re-establishes natural blood flow patterns in peripheral vascular and arteriovenous grafts - helping to keep damaged blood vessels open for longer and improving outcomes for patients.
Bill Allan, CEO, says, "We are very pleased to see this high quality study published in a prestigious journal and are encouraged by the key findings within the paper. It's clear that Spiral Flow(TM) Grafts enhance patient outcomes. We will continue to develop more clinical experience and data sets and look forward to wider awareness of the true impact of our Spiral Flow(TM) products on patients' lives."
For more information:
For more press information contact:
Bill Allan: +44-(0)7920-143-030
Kate Full: +44-(0)1382-598-532
Caroline Thoms: +44-(0)1382-598-532
SOURCE Vascular Flow Technologies